Roger P A'Hern

Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial

Emma Hall, Kevin J Harrington, S. Bhide, 2011, The Lancet. Oncology.

Widening eligibility to phase II trials: constant arcsine difference phase II trials.

R. A’Hern, Roger P A'Hern, 2004, Controlled clinical trials.